This is likely an oversimplification, but I've been looking for exactly this diagram Inhibiting various TYKs/JAKs corresponds to various downstream cytokine inhibition @EricFMorand does it make sense to see this as anifrolumab+ustekinumab? No? @rheumnow #ACR24 Abstr#0662 https://t.co/thti6s5TR3

• https://x.com/EBRheum/status/1857836781628174735/photo/1
• https://x.com/EBRheum/status/1857836781628174735/photo/1

A study from the EuroSpA collaboration validates new BASDAI cut-offs for disease activity in axial spondyloarthritis based in ASDAS: <1.4 for remission, <2.8 for low activity, and >5.9 for very high activity. This research enhances our understanding of disease states and their… https://t.co/OkPiTwSHz6 https://t.co/NjIDeme9dm

• https://x.com/i/web/status/1857834768945262963
• https://x.com/synovialjoints/status/1857834768945262963/photo/1

Ok so trivial tweet here but I just love the name of this outcome measure... "LFA-REAL" 😄😆 Serious topic though; PRO's are huge in SLE research! @RheumNow #ACR24 Abstr#0626 https://t.co/w34zTNjSbH

• https://x.com/EBRheum/status/1857834013425311941/photo/1

The use of ultrasound in clinically suspect arthralgia can complement MRI early diagnosis of RA. Abstr#228 Gupta A @RheumNow #ACR24 https://t.co/rpVqZKeMXE

• https://x.com/synovialjoints/status/1857832973745127465/photo/1

#0600 🔬BKZ achieves sustained impact in PsA ➡️ BE OPTIMAL & BE COMPLETE trials:BKZ 160 mg Q4W bDMARD-naïve & TNFi-IR PsA pts ➡️Pain,function,fatigue & skin showed greatest & sustained reductions @ 2 yrs👇 🎯BKZ offers sustained response in 🔑PsA domains #ACR24 @RheumNow https://t.co/uhzZoOrr3H

• https://x.com/CaoilfhionnMD/status/1857832755188686893/photo/1

🌟 Join us for the Aging Strong session at #ACR24! We are thrilled to have Dr Cynthia Boyd, division director of Geriatrics at Hopkins, visit us to discuss how to manage multicomplexity in older rheumatic patients. #GeriRheum @RheumNow @cynthiaboyd16 @UnaMakris https://t.co/QZpOmdgzOR

• https://x.com/JihaRheum/status/1857832252148728191/photo/1

A 6-year study of the link between alcohol consumption and spinal radiographic progression in axial spondyloarthritis (axSpA). Results indicate that alcohol may worsen spinal damage, particularly in males and those with radiographic axSpA. Future research should explore… https://t.co/IIvTyq7kBe

• https://x.com/i/web/status/1857830999583080712

Using #MachineLearning for predicting flares in axSpA @DiegoBenavent et al, data from METEOR-SpA registry showed the ff predictors of flares thru the reduced logistic regression model: 🔅lower ASDAS 🔅enthesitis 🔅prior flares 🔅longer treatment duration @RheumNow #ACR24 abs559 https://t.co/wyIo9gnKVJ

• https://x.com/RHEUMarampa/status/1857830422023123171/photo/1

📈 Data from @UIowa_Rheum on how rurality impacts delay to diagnosis in #GCA 📍 0747 👉🏼 People living in more rural areas have an increased time to diagnosis & treatment- further prospective studies needed to delineate effects of rurality further @RheumNow #ACR24 @LemonReneeNi https://t.co/3YMcI9ha3T

• https://x.com/DrMiniDey/status/1857830313071677758/photo/1

Harkins @DrTrishHarkins et al. People with PMR exhibit an accelerated physical aging phenotype at baseline. High rates of frailty (41%), pre-frailty (28%), cognitive impairment (74%!), sarcopenia (23%), osteoporosis (21%) @RheumNow #ACR24 Abstr#0740 https://t.co/4ZT8VtGi1W https://t.co/xBQ5CLlb5A

• Evaluation of an Accelerated Physical Aging Phenotype in Newly Diagnosed Patien…
• https://x.com/RichardPAConway/status/1857830238534635630/photo/1

Does apremilast have cardiometabolic benefits? Abstract 0598: In PsA patients, 1-year treatment with apremilast associated w/ ↓ body fat mass, including android fat, and was linked w/ improved disease activity (DAS28-CRP). #ACR24 @RheumNow https://t.co/11n4gQN7Xo

• https://x.com/AkhilSoodMD/status/1857829735235035286/photo/1

Characteristics of difficult-to-treat AS accdg to a retrospective study by @DaoudAnsaam @mmagrey1 et al ⬆️ BMI + comorbidities: HTN, CKD, depression + EAMs: IBD, Pso, iridocyclitis + HLA-B27 Interesting real world data. @RheumNow #ACR24 abs573 https://t.co/GlE4tFpsSz

• https://x.com/RHEUMarampa/status/1857829538748571674/photo/1

FDA has given FDA Breakthrough Therapy designation to Nipocalimab for treatment of adults w/ moderate-to-severe Sjögren’s disease. NIPO is an Ab to neonatal Fc receptor (FcRn), & was tested and shown effective in Sjog in the Phase 2 DAHLIAS study - a plenary presentation at… https://t.co/aQDp7iPKXD https://t.co/hJ8fe6JwxC

#0588 🔬 Sex Differences in PsA ➡️n=1405, pooled RCT data ♀️49%: Milder PsO (PASI 7.8 v 11.5), higher BMI, longer PsA duration,⬆️ fatigue/pain vs ♂️ ♀️worse QoL/functional impairment ♂️More dactylitis (45% v 37%) 🩺 Sex-specific factors matter in PsA #ACR24 @RheumNow

Puechal et al. Serial ANCA testing may predict relapse in a large group of AAV patients but is NOT useful for individual patients. @RheumNow #ACR24 Abstr#0721 https://t.co/ClvTk2Tlar https://t.co/k4vc7l9jzK

• Does Serial ANCA Testing Help Predict the Risk of Relapse in Granulomatosis wit…
• https://x.com/RichardPAConway/status/1857827722002571721/photo/1